KENNETH R HESS to Research Design
This is a "connection" page, showing publications KENNETH R HESS has written about Research Design.
Connection Strength
0.462
-
Statistical issues in clinical trial design. Curr Oncol Rep. 2007 Jan; 9(1):55-9.
Score: 0.172
-
Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials. Clin Cancer Res. 2016 Sep 01; 22(17):4291-301.
Score: 0.083
-
Effect of molecular disease subsets on disease-free survival in randomized adjuvant chemotherapy trials for estrogen receptor-positive breast cancer. J Clin Oncol. 2008 Oct 01; 26(28):4679-83.
Score: 0.048
-
Impact of phase II trials with progression-free survival as end-points on survival-based phase III studies in patients with anaplastic gliomas. BMC Cancer. 2007 Jun 22; 7:106.
Score: 0.044
-
Clinical trial design for microarray predictive marker discovery and assessment. Ann Oncol. 2004 Dec; 15(12):1731-7.
Score: 0.037
-
Microarrays: handling the deluge of data and extracting reliable information. Trends Biotechnol. 2001 Nov; 19(11):463-8.
Score: 0.030
-
Phase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastoma. Cancer. 2019 02 01; 125(3):424-433.
Score: 0.024
-
Comparison of Residual Risk-Based Eligibility vs Tumor Size and Nodal Status for Power Estimates in Adjuvant Trials of Breast Cancer Therapies. JAMA Oncol. 2018 Apr 12; 4(4):e175092.
Score: 0.023